Policy Developments - The National Healthcare Security Administration held the fourth session of a series of discussions on supporting innovative drugs and medical devices, focusing on the current status, challenges, and development directions of innovative drug research and development [2] Drug and Device Approvals - Changchun High-tech announced that its subsidiary, Beili Nian, received FDA approval for the oral solution of Amlodipine Besylate, specifically designed for children over 6 years old and adults with swallowing difficulties, enhancing the company's competitiveness in the U.S. market [4] - Jianfeng Group's subsidiary received approval from the National Medical Products Administration for the chemical raw material drug Empagliflozin, allowing it to be sold in the domestic market, which will help expand its business scope [5] Financial Reports - Guobang Pharmaceutical reported a net profit of 456 million yuan for the first half of 2025, with a revenue of 3.026 billion yuan, reflecting a year-on-year growth of 4.63% in revenue and 12.6% in net profit [7] Capital Market Activities - Tigermed announced that its wholly-owned subsidiary acquired 56.37% of Japanese MICRON for 484 million yen, equivalent to approximately 23.48 million yuan [9] - WuXi AppTec plans to adjust the maximum repurchase price of its shares from 90.72 yuan to 114.15 yuan per share, while keeping other details of the repurchase plan unchanged [10] Industry Developments - Jiangsu Province's Medical Security Bureau announced the pricing for brain-computer interface-related medical services, with non-invasive adaptation fees set at 966 yuan per session and invasive implantation fees at 6,600 yuan per session [12] - The pricing initiative aims to prevent market disorder and high pricing, accelerating treatment solutions for conditions like epilepsy and Parkinson's disease [13] Shareholder Actions - Jiahe Meikang announced that its shareholder, Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, plans to reduce its stake by up to 3.0%, equating to a maximum of 4.1276 million shares [16]

尖峰集团(600668.SH)公告称，全资子公司尖峰药业收到国家药品监督管理局关于化学原料药恩格列净 的《化学原料药上市申请批准通知书》，该原料药已符合国家相关原料药审评技术标准，可在国内市场 进行销售，有助于拓展业务领域。但需注意医药产品具有高科技、高风险、高附加值的特点，药品的生 产和销售容易受到国家政策、市场环境变化等因素影响，存在较大不确定性。 ...